| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-28142
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-28122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-28123 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5169
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 |
| filingDate |
2015-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_681358cd5efd8d71854128c8785c6196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa8c85e6dc3160b6d0e5ef5f01197f61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b95dabfd7db8fd59b9c49da43a371dd8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63d982c543fe06092cf2cd015b49c1f6 |
| publicationDate |
2018-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10053494-B2 |
| titleOfInvention |
Chemically activated nanocapsid functionalized for cancer targeting |
| abstract |
Modified capsid proteins containing at least a portion of hepatitis E virus (HEV) open reading frame 2 (ORF2) having one or more cysteine residues in a surface variable loop or the C-terminus of HEV ORF2, or a portion thereof, are provided. The modified capsid proteins can be used to form hepatitis E virus (HEV) virus like particles (VLPs) having cysteine functional groups exposed on the outer-surface. The exposed cysteine functional groups can be modified via their thiol reactive group. For example, a bioactive agent, such as a cell-targeting ligand, can be conjugated to the one or more cysteines for targeted delivery of chemically activated nanocapsids. |
| priorityDate |
2014-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |